The stock of Advaxis, Inc. (NASDAQ:ADXS) is a huge mover today! About 427,616 shares traded hands. Advaxis, Inc. (NASDAQ:ADXS) has declined 16.92% since April 4, 2016 and is downtrending. It has underperformed by 18.01% the S&P500.
The move comes after 5 months positive chart setup for the $343.09 million company. It was reported on Nov, 4 by Barchart.com. We have $16.37 PT which if reached, will make NASDAQ:ADXS worth $319.07 million more.
Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage
Out of 2 analysts covering Advaxis (NASDAQ:ADXS), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Advaxis has been the topic of 2 analyst reports since September 11, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating by Barclays Capital given on Tuesday, September 22. The firm earned “Buy” rating on Friday, September 11 by Guggenheim.
According to Zacks Investment Research, “Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body’s immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company’s products in development include Lovaxin C and Lovaxin B, Lovaxin P.”
Insitutional Activity: The institutional sentiment increased to 2.38 in 2016 Q2. Its up 1.20, from 1.18 in 2016Q1. The ratio improved, as 7 funds sold all Advaxis, Inc. shares owned while 14 reduced positions. 11 funds bought stakes while 39 increased positions. They now own 21.74 million shares or 0.17% less from 21.77 million shares in 2016Q1.
Miller Invest Management Lp last reported 14,000 shares in the company. Pnc Fincl Services holds 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 21,500 shares. Manufacturers Life Insurance Company The holds 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 23,714 shares. Zacks Management last reported 12,317 shares in the company. Blackrock Inv Management Ltd Limited Liability Company last reported 0% of its portfolio in the stock. Birchview Limited Partnership, a Vermont-based fund reported 35,600 shares. Weiss Multi has 0.03% invested in the company for 41,553 shares. Bnp Paribas Arbitrage Sa, a New York-based fund reported 1,300 shares. Barclays Public Limited Liability Company accumulated 0% or 130 shares. Great West Life Assurance Com Can holds 0% or 5,100 shares in its portfolio. Creative Planning reported 29,280 shares or 0% of all its holdings. Tower Rech Ltd (Trc) accumulated 699 shares or 0% of the stock. Northern reported 386,249 shares or 0% of all its holdings. Nationwide Fund Advsrs has 0% invested in the company for 21,302 shares. State Board Of Administration Of Florida Retirement System accumulated 0% or 20,295 shares.
Insider Transactions: Since May 13, 2016, the stock had 0 buys, and 6 insider sales for $1.14 million net activity. SIDRANSKY DAVID sold 22,808 shares worth $342,348. On Monday, August 8 the insider BERMAN RICHARD J sold $520,755. On Friday, May 13 MCKEARN THOMAS J sold $30,545 worth of the stock or 4,100 shares. Mayes – Gregory T. sold 19,162 shares worth $157,703. O’Connor Daniel also sold $68,557 worth of Advaxis, Inc. (NASDAQ:ADXS) on Monday, October 31. PETIT ROBERT also sold $23,271 worth of Advaxis, Inc. (NASDAQ:ADXS) shares.
Another recent and important Advaxis, Inc. (NASDAQ:ADXS) news was published by Globenewswire.com which published an article titled: “Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2” on October 24, 2016.
ADXS Company Profile
Advaxis, Inc., incorporated on February 28, 2002, is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies. The Company’s Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants. The Company’s immunotherapy candidates include Axalimogene filolisbac (ADXS-HPV), ADXS-PSA and ADXS-HER2.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.